Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity

Authors Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

Published 17 November 2009 Volume 2009:4 Pages 421—430

DOI https://doi.org/10.2147/COPD.S6300

Review by Single-blind

Peer reviewer comments 3

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, Michael V Burke, JT Hays

Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Keywords: smoking cessation, chronic obstructive pulmonary disease, varenicline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al

Patient Preference and Adherence 2010, 4:355-362

Published Date: 13 September 2010

Readers of this article also read:

Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease

Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1155-1161

Published Date: 17 June 2015

Cytotoxic effects of curcumin in osteosarcoma cells

Moran JM, Rodriguez-Velasco FJ, Roncero-Martin R, Vera V, Pedrera-Zamorano JD

International Journal of Nanomedicine 2014, 9:5273-5275

Published Date: 14 November 2014

Anticancer nanodelivery system with controlled release property based on protocatechuate–zinc layered hydroxide nanohybrid

Barahuie F, Hussein MZ, Abd Gani S, Fakurazi S, Zainal Z

International Journal of Nanomedicine 2014, 9:3137-3149

Published Date: 26 June 2014

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:629-645

Published Date: 16 June 2014

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:353-363

Published Date: 23 June 2011

Fatigue in patients with COPD participating in a pulmonary rehabilitation program

Cindy J Wong, Donna Goodridge, Darcy D Marciniuk, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:319-326

Published Date: 13 September 2010

Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity

Joseph Finkelstein, Eunme Cha, Steven M Scharf

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:337-349

Published Date: 4 September 2009

Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®

Rick Hodder, Pat Ray Reese, Terra Slaton

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:225-232

Published Date: 26 May 2009